On December 18, 2025 BioNTech SE (Nasdaq: BNTX, "BioNTech", or "the Company") reported the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, "CureVac") and that the subsequent offering period (the "Subsequent Offering Period") of the exchange offer (the "Offer") for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously published, as of the expiration time of the Subsequent Offering Period, a total of 195,341,219 CureVac shares, collectively representing approximately 86.75% of CureVac’s issued and outstanding shares, were validly tendered in the Offer, of which 11,269,809 CureVac shares were validly tendered in the Subsequent Offering Period. Considering the final exchange ratio of 0.05363 of a BioNTech American Depositary Share ("ADS") per CureVac share as published on November 26, 2025 and the payment of cash in lieu of fractional BioNTech ADSs, in total, 10,475,287 BioNTech ADSs have been, or will be, delivered to tendering holders of CureVac shares, of which 604,201 BioNTech ADSs will be delivered to holders tendering during the Subsequent Offering Period.

(Press release, BioNTech, DEC 18, 2025, View Source [SID1234661527])